Published in Vaccine Weekly, February 16th, 2000
"Within the framework of ongoing studies on the identification of Onchocerca volvulus molting larval antigens as potential targets for vaccine development, we used a well-defined serum pool from putatively immune (PI) individuals to immunoscreen an O. volvulus third-stage larval (L3) cDNA expression library (SAW94WL-OvL3)," wrote W. Tawe and colleagues from the Lindsley F. Kimball Research Institute, New York. "We present the characterization of one of the isolated clones, the Ov-VAA-1."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly